技术指标
指标
数值
方向
MACD(12,26,9)
-0.045
卖出
RSI(14)
34.637
中性
STOCH(KDJ)(9,3,3)
39.913
买入
ATR(14)
0.128
低波动
CCI(14)
-67.234
中性
Williams %R
72.157
卖出
TRIX(12,20)
-1.435
卖出
StochRSI(14)
100.000
超买
搜索
Beyondspring Inc
BYSI添加自选
1.170USD
-0.015-1.27%
收盘 07-28 16:00（美东）报价延迟15分钟
48.11M总市值
亏损市盈率 TTM
关键数据
1.190今开
1.210最高
6.62K成交量
亏损市盈率 TTM
--市盈率动
--股息TTM
0.02%换手率
1.185昨收
1.130最低
4.57K成交额
亏损市盈率静
-1.40市净率
0.00%股息率 TTM
-30.56%ROA
3.44052周最高
0.22量比
-11.12M净利润
41.12M总股本
-0.1885每股收益TTM
0.43Beta
-321.46%ROE
1.17552周最低
6.74%振幅
100.00%毛利率
48.11M总市值
-5.63回报/风险
5.73%风险率
TradingKey Beyondspring Inc股票评分
单位: USD 更新时间: 2026-07-28操作建议
Beyondspring Inc当前公司基本面数据相对非常健康，增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名185/385位。机构持股占比非常高，中期看，股价处于下降通道。近一个月，市场表现非常差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Beyondspring Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看好
Beyondspring Inc亮点
亮点风险
BeyondSpring Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to improve clinical outcomes for patients with high unmet medical needs. Its lead asset, Plinabulin, is in late-stage clinical development as an anti-cancer agent in non-small cell lung cancer (NSCLC) and a range of cancer indications. The Company’s mechanism of action as a dendritic cell maturation agent supports both anti-cancer activity and immune modulation, offering an approach to resensitizing tumors to checkpoint inhibitors. It also has a pipeline of immuno-oncology product candidates, BPI-002 program, which is based on an oral small molecule agent that increases T-cell co-stimulation; BPI-003 program, which is based on a small molecule inhibitor of IKK, a protein kinase, and BPI-004 program, which is focused on a small molecule that induces the production of neo-antigens by tumor cells, allowing tumors containing no immune cells to be infiltrated by the immune system.
分析师目标
根据
0
位分析师
--
评级
--
目标均价
--
涨幅空间
Beyondspring Inc新闻
即将为您带来更多新闻，敬请期待。。。
技术指标
移动平均线
指标
数值
方向
MA5
1.137
买入
MA10
1.201
卖出
MA20
1.410
卖出
MA50
1.533
卖出
MA100
1.573
卖出
MA200
1.665
卖出
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Beyondspring Inc简介
BeyondSpring Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to improve clinical outcomes for patients with high unmet medical needs. Its lead asset, Plinabulin, is in late-stage clinical development as an anti-cancer agent in non-small cell lung cancer (NSCLC) and a range of cancer indications. The Company’s mechanism of action as a dendritic cell maturation agent supports both anti-cancer activity and immune modulation, offering an approach to resensitizing tumors to checkpoint inhibitors. It also has a pipeline of immuno-oncology product candidates, BPI-002 program, which is based on an oral small molecule agent that increases T-cell co-stimulation; BPI-003 program, which is based on a small molecule inhibitor of IKK, a protein kinase, and BPI-004 program, which is focused on a small molecule that induces the production of neo-antigens by tumor cells, allowing tumors containing no immune cells to be infiltrated by the immune system.
公司代码BYSI
公司Beyondspring Inc
CEOHuang (Lan)
网址https://www.beyondspringpharma.com/en/
公司股东
相关品种
热门品种
常见问题
Beyondspring Inc(BYSI)的当前股价是多少？
Beyondspring Inc(BYSI)的当前股价是 1.17。
Beyondspring Inc的股票代码是什么？
Beyondspring Inc的股票代码是BYSI。
Beyondspring Inc股票的52周最高点是多少？
Beyondspring Inc股票的52周最高点是3.44。
Beyondspring Inc股票的52周最低点是多少？
Beyondspring Inc股票的52周最低点是1.18。
Beyondspring Inc的市值是多少？
Beyondspring Inc的市值是48.73M。
Beyondspring Inc(BYSI)股票的每股收益（EPS TTM）是多少
Beyondspring Inc(BYSI)股票的每股收益（EPS TTM）是-0.02。